SPRY Silverback Therapeutics Inc

$7.59

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Silverback Therapeutics Inc

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to food, medication, and insect stings. The company is headquartered in San Diego, California.

Website: https://ars-pharma.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1671858
Address
500 FAIRVIEW AVENUE NORTH, SUITE 600, SEATTLE, WA, US
Valuation
Market Cap
$1.46B
P/E Ratio
186.00
PEG Ratio
nan
Price to Book
5.69
Performance
EPS
$0.08
Dividend Yield
—
Profit Margin
8.97%
ROE
3.28%
Technicals
50D MA
$12.18
200D MA
$12.74
52W High
$18.51
52W Low
$7.55
Fundamentals
Shares Outstanding
98M
Target Price
$31.60
Beta
0.98

SPRY EPS Estimates vs Actual

● Estimated
● Actual

SPRY News & Sentiment

Nov 10, 2025 • Motley Fool SOMEWHAT-BULLISH
ARS Pharma SPRY Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Monday, Nov. 10, 2025 at 8:30 a.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
Nov 10, 2025 • Zacks Commentary NEUTRAL
ARS Pharmaceuticals, Inc. ( SPRY ) Reports Q3 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -15.56% and +14.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nov 10, 2025 • GlobeNewswire NEUTRAL
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® ( epinephrine nasal spray )
$32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of ...
Nov 06, 2025 • Zacks Commentary NEUTRAL
Lipocine ( LPCN ) Reports Q3 Loss, Tops Revenue Estimates
Lipocine (LPCN) delivered earnings and revenue surprises of -5.36% and +15.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nov 05, 2025 • Zacks Commentary NEUTRAL
NewAmsterdam Pharma Company N.V. ( NAMS ) Reports Q3 Loss, Lags Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of -7.89% and -91.03%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nov 03, 2025 • Benzinga NEUTRAL
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology ( ACAAI ) Annual Scientific Meeting - ARS Pharmaceuticals ( NASDAQ:SPRY )
ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy® ( epinephrine nasal spray ) Oral presentation to report results from real world data on the effectiveness of epinephrine nasal spray in clinical practice
Sentiment Snapshot

Average Sentiment Score:

0.163
50 articles with scored sentiment

Overall Sentiment:

Bullish

SPRY Reported Earnings

Aug 13, 2025
Jun 30, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.46
  • Estimate: $-0.46
  • Whisper: —
  • Surprise %: 0.0%
May 14, 2025
Mar 31, 2025 (Pre market)
-0.24 Surprise
  • Reported EPS: $-0.35
  • Estimate: $-0.11
  • Whisper: —
  • Surprise %: -218.2%
Mar 20, 2025
Dec 31, 2024 (Pre market)
0.63 Surprise
  • Reported EPS: $0.51
  • Estimate: $-0.12
  • Whisper: —
  • Surprise %: 534.0%
Nov 13, 2024
Sep 30, 2024 (Pre market)
-0.05 Surprise
  • Reported EPS: $-0.20
  • Estimate: $-0.15
  • Whisper: —
  • Surprise %: -33.3%
Aug 06, 2024
Jun 30, 2024 (Post market)
-0.01 Surprise
  • Reported EPS: $-0.13
  • Estimate: $-0.12
  • Whisper: —
  • Surprise %: -8.3%
May 09, 2024
Mar 31, 2024 (Post market)
0.0 Surprise
  • Reported EPS: $-0.11
  • Estimate: $-0.11
  • Whisper: —
  • Surprise %: 0.0%
Mar 21, 2024
Dec 31, 2023 (Post market)
0.07 Surprise
  • Reported EPS: $-0.07
  • Estimate: $-0.14
  • Whisper: —
  • Surprise %: 50.0%
Nov 09, 2023
Sep 30, 2023 (Post market)
0.02 Surprise
  • Reported EPS: $-0.16
  • Estimate: $-0.18
  • Whisper: —
  • Surprise %: 11.1%
Aug 10, 2023
Jun 30, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $-0.18
  • Estimate: $-0.17
  • Whisper: —
  • Surprise %: -5.9%

Financials